quarter solid whether reflect stabil
improv cloud easier comparison
continu believ impella enter period lower
quarter post total revenu vs mse
world-wide impella revenu vs mse servic
revenu vs mse manag commentari suggest
improv quarter relat recent clinic public
pressur first emerg follow present aha expect
rel insul given geograph mix
predominantli us lesser extent europ minim china exposur
quarter repres estim compar
favor peer averag total revenu reflect flat y/i
growth impella would adjust
impact vs mse revenu q/q two-year
stack momentum deceler consecut quarter even adjust
guidanc provid expect
quarter mark trough key issu quarter clearli whether
result mark inflect stabil busi less
construct thesi tie structur lower growth believ
upper single-digit adjust growth continu momentum deceler
impact view qualit commentari earli march saw sequenti
growth y/i growth first week march encourag
impella durabl amid rel impact cloud view given
assum impella durabl devic part phase
recoveri model potenti impella use shock patient
insul geograph mix easier comp creat rp
issu year-ago period continu model evid
improv beyond note manag
commentari point optim around back-half recoveri access return
cath lab capac prove sourc constraint procedur recoup
note somewhat off-set continu roll-out
refin model lower number reflect close
y/i revenu declin assum sequenti recoveri
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
april trough continu expect high risk pci emerg
procedur recov quickli number may prove conserv
expect oper margin contract neighborhood primarili
result gross margin pressur minim scale-back spend
partial off-set sg reduct margin see sequenti improv
model continu expect impella revenu recov pre-
covid estim later exhibit detail model
ecmo strategi compani announc yesterday acquisit breeth
develop novel ecmo system complement portfolio
compani histor question overutil ecmo among patient
necessarili requir oxygen highlight today benefit
combin ecmo therapi impella ecpella alreadi repres
patient popul today ad ecmo technolog could
allow treat shock patient requir oxygen alreadi
support impella add ecmo pediatr offer treat new
patient respiratori failur breeth plan
limit market releas expect detail deal
could inform financi implic upcom virtual analyst day next
thesi structur growth remain phase recoveri model group
coverag three phase phase includ supplier insul
posit off-set busi phase includ tradit implant phase
includ discretionari implant capit intens busi recoveri
model place phase acut implant drove rel
out-performance pandem said core thesi continu
zero pressur look structur transient
address market catalyst ecp btr stemi potenti year away
cloud path acceler expand sheath ecp timelin remain
track expand sheath us roll-out ecp ef commenc
year plan data public includ recent jama public
studi could continu creat nois around referr channel
although like partial off-set compani activ educ
roadshow effort well continu underscor need robust
data use impella appropri patient popul note
revers sinc tct around willing run random
clinic trial high-risk pci cardiogen shock patient protect iv
continu view long-term posit result studi
avail year
abiom slowdown structur transient
price target support dcf assum wacc
termin growth impli multipl base case sale repres
discount high growth devic peer
growth slow seen prior
year teen y/i growth impella growth
slowdown becom structur
margin expans pace slow stand
origin lrp
reimburs could head lower
stemi pivot trial continu
repres key longer term tam
expans opportun market
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
impella penetr take faster
expect util increas exist
impella site driven new product
launch incres data expans
effort organ growth sustain
double-digit longer tail stemi
opportun posit feasibl day
multipl expand higher growth
durabl longer
dcf analysi equat
impact less pronounc
expans opportun posit
feasibl data multipl
high growth peer lack competit
peer protabl balanc
transit matur adopt
consensu
view descript risk reward theme
recoveri prolong mid
anomal impella sale growth
deceler doubl digit multipl
contract reect slower growth prole
potenti market size disappoint and/or
expans delay
sustain reimburs broader drg
pma approv rp launch ecp
broader commerci launch japan
us stemi impli
view explan region hierarchi
research highest favor quintil
faster expect impella roll-out
revers trend prior year propos
faster expect stemi expans
neg headlin impact
impact meaning
emerg competit ahead expect
market present attract opportun
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
sale
sale
sale
sale
invest
st debt current portion lt debt
loss sale properti equip
net chang work capit
purchas invest
sale invest
net invest
chang equiti
effect exchang rate chang
net financ
begin year
end year
